A novel approach to PAAD patient care: A 9-cuproptosis-related differential expression lncRNAs model for prognosis prediction

Abstract

Cuproptosis is a novel type of programmed cell death that is being linked to varied malignancy activities. Long non-coding RNAs (lncRNAs) are demonstrating an increasing ability to influence the progression of cancer and the immune microenvironment. As a result, using the TCGA database, we attempted to construct a cuproptosis-related lncRNAs risk model to predict the prognosis of pancreatic adenocarcinoma (PAAD) and identify the relationship between the risk model and the tumor immune microenvironment (TME). The Cox proportional hazards model and the Least Absolute Shrinkage and Selection Operator (LASSO) determined a 9-CuRDEPLs (Cuproptosis-related differential expression prognostic lncRNAs) prognostic risk model. Kaplan-Meier (K-M) and receiver operating characteristic (ROC) curves validate the accuracy of the model. Multivariate Cox analysis employing a risk score as well as patients' clinical parameters shows that a risk score can independently predict the prognosis of PAAD. A nomogram was created, exhibiting that the risk model was capable of accurately predicting the overall survival of PAAD patents for 1, 3, and 5 years. The link between the immunological features and 9-CuRDEPL's model was also investigated further. The findings suggest that TME, particularly CD8+ cells, differs from high to low risk groups. The drug correlation assay reveals that nine CuRDEPLs have a strong relationship with the sensitivity of certain drugs. All of these suggest that 9-CuRDEPL's model could be utilized to forecast the prognosis of PAAD and will help guide clinical therapy for pancreatic cancer.